Laboratoires Pierre Fabre SA (Pierre Fabre), a subsidiary of the Pierre Fabre Foundation, is primarily engaged in the development and distribution of pharmaceutical and dermo-cosmetic products. The company operates in the healthcare and beauty industries, focusing on prescription drugs, dermo-cosmetics, and consumer healthcare products. As of December 2024, the company operated in 43 locations globally and offered its products to more than 120 countries. The company is involved in the development of prescription drugs for various therapeutic fields such as oncology, urology, diabetes, chronic respiratory illnesses, and allergies. It also offers solutions for chronic diseases and everyday ailments, including family health, hygiene, and oral care products. The company's dermo-cosmetic brands include Eau Thermale Avene, A-Derma, Ducray, Klorane, Dexeryl, Darrow, and Rene Furterer, which focus on skin and hair care. It also emphasizes natural health care through its Naturactive brand, which offers products based on plant-based active ingredients. The company collaborates with healthcare professionals, various alliance partners, distributors, and patient associations to offer its products.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Pierre Fabre actively engages in research and development (R&D) initiatives across various domains, including oncology, dermatology, dermo-cosmetics, and consumer health care. The company develops innovative solutions by leveraging advanced technologies such as artificial intelligence and data science. Pierre Fabre emphasizes precision medicine, targeted biotherapies, and immunotherapy in oncology while advancing dermo-cosmetic products. The company collaborates with healthcare professionals and partners to enhance its R&D efforts and address unmet medical needs. Pierre Fabre's R&D activities are managed through several specialized units, including pharmaceutical R&D centers in France, which focus on oncology, dermatology, and consumer health care. The company also has innovation centers in Asia and Latin America to understand local consumer needs and develop region-specific products. These units are responsible for conducting research, developing new therapeutic and cosmetic solutions, and ensuring the safety and efficacy of products. The company operates two pharma R&D centers in France and six dermo-cosmetic R&D centers in France. The dermo-cosmetic R&D centers conduct more than 1000 studies yearly. Some of the pipeline projects under the R&D pharma centers are BRAF inhibitor, BRAF inhibitor + MEK inhibitor, Pan-RAF small molecule inhibitor, mutant-selective EGFR-exon20 small molecule inhibitor, and anti-cMET antibody degraded. In FY2024, the company spent EUR219 million on R&D, which, as a percentage of revenue, stood at 7.1% and grew 15.2% YoY. As of December 2024, under the pharmaceutical branch, the company has 2,800 patent applications; and 24 new patents filed in FY2024. Under the dermo-cosmetic branch, it had 126 patents; 1,142 patent applications; and 13 new patents filed in FY2024.